All In MedTech

FDA Clearance Tracker · DEN190032

HemosIL Liquid Anti-Xa

A De Novo grant creates a new device type for a low to moderate risk device with nothing on the market to compare it to. Later devices of this type can use it as their comparison in a 510(k).

Last checked: Nov 19, 2026Latest source record: Sep 17, 2020 (this decision)Source: openFDAMethods & limitations

De NovoNew device type

Decided

Sep 17, 2020

De Novo granted

Time to decision

450 days

Received Jun 25, 2019. Calendar days, including time FDA spent waiting on the applicant.

Pathway

De Novo

Direct

Device class

Class II

The decision

FDA number
DEN190032
Device name
HemosIL Liquid Anti-Xa
Applicant location
Bedford, MA
Received
Jun 25, 2019
Decided
Sep 17, 2020
Decision
De Novo granted
Submission type
Direct

Device type

Device class
Class II
Regulation
21 CFR 864.7295

Every decision under product code QLU

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Instrumentation Laboratory CO

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.